PHARMACOKINETIC PROFILE OF 75 MG CLOPIDOGREL IN PLASMA OF INDONESIAN HEALTHY SUBJECTS BY ULTRA HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY
DOI:
https://doi.org/10.22159/ijap.2018.v10s1.73Keywords:
Clopidogrel, Ultra-high-performance liquid chromatography-tandem mass spectrometry, Plasma, Pharmacokinetic profile, BioanalysisAbstract
Objective: This study aimed to determine clopidogrel in plasma to obtain its pharmacokinetic profile using ultra-high-performance liquid
chromatography-tandem mass spectrometry (UPLC-MS/MS).
Methods: Clopidogrel analysis was performed in vivo by UPLC-MS/MS using validated methods. Subjects received 75 mg clopidogrel, and plasma
samples were collected at 14 time points after 0 baseline (pre-dose): 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 8, 12, 18, and 24 h.
Results: A linear calibration curve was produced in the range of 20–5.000 pg/mL. This method fulfills the criteria for validation according to the
European Medicines Agency guidelines. The obtained pharmacokinetic profile of clopidogrel was as follows: Maximum concentration=1.146 ng/mL,
time at maximum concentration (tmax)=1 h, half-life (t½)=7.01 h, area under curve (AUC)0−t=7.420 ng h/mL, and AUC0−t=8.111 ng h/mL.
Conclusion: Clopidogrel analysis using a UPLC/MS-MS system with liquid-liquid extraction method was successfully conducted using plasma samples
from three healthy subjects who administered 75 mg of clopidogrel tablet.
Downloads
References
European Medicines Agency. Assessment Report for Clopidogrel Teva.
London: European Medicines Agency; 2009.
Indonesia National Agency of Food and Drug Control. Regulation
from Head of Indonesia National Agency of Food and Drug Control
No. HK.03.1.23.12.11.10217 about Drugs Obligate Equivalence Test.
Jakarta; 2011. [In Indonesian]
Alesci J, Victorino A. Clopidogrel. New York: Nova Biomedical/Nova
Science; 2014.
Bhargav K, Venkata SB, Venkata SK, Himaja G, Samuel GG,
Bhaskar RK. Pharmacokinetic drug interaction between clopidogrel
and esomeprazole in adult healthy male volunteers. Asian J Pharm Clin
Res 2017;10:336-41.
Gurupadayya BM, Sama S. Bio-analytical determination of clopidogrel
and pantoprazole by RP-HPLC method in rat plasma: Application to
drug interaction study. Asian J Pharm Clin Res 2014;7:10-3.
Reddy DN. Design, development and characterization of clopidogrel
bisulfate transdermal drug delivery system. Asian J Pharm Clin Res
;8:277-80.
Harahap Y. Role of Bioanalysis in Assuring Drug Quality and Increasing
Quality of Patient Life. Depok: UI Press; 2010.
KarazÌniewicz-Åada M, Danielak D, Teżyk A, Żaba C, Tuffal G,
Główka F. HPLC–MS/MS method for the simultaneous determination
of clopidogrel, its carboxylic acid metabolite and derivatized isomers of
thiol metabolite in clinical samples. J Chromatogr B 2012;911:105-12.
Divi KR, Jayaveera KN, Naidu YK, Reddy MK. Development and
validation of high-throughput liquid chromatography–tandem mass
spectrometric method for simultaneous quantification of clopidogrel
and its metabolite in human plasma. J Chromatogr B 2010;878:502-8.
Zou JJ, Tan J, Fan HW, Chen SL. Bioequivalence study of clopidogrel
mg tablets in healthy male volunteers. J Bioequiv Bioavailab
;4:6-9.
European Medicines Agency. Guideline on Bioanalytical Method
Validation. London: European Medicines Agency; 2011.
Robinson A, Hillis J, Neal C, Leary AC. The validation of a
bioanalytical method for the determination of clopidogrel in human
plasma. J Chromatogr B 2007;848:344-54.
Published
How to Cite
Issue
Section
